★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Evolving COVID Variants May Render Current Treatments Obsolete, Drive Need for New Round of Therapeutics The COVID-19 omicron variant has diminished the efficacy of the US's most prominent antibody treatments. As the genome of this virus constantly…McAlinden Research PartnersJanuary 4, 2022
★ Daily Intelligence Briefings (DIBs)⦁ Theme TrackerServicesTransportation Cruise Line Customers Shrugging Off Omicron Variant as Travel Demand Continues to Rebound Cruise stocks slumped throughout November, primarily due to concerns around the new COVID-19 omicron variant. Investors have been fearful that near-term…McAlinden Research PartnersDecember 13, 2021